Replies to post #176607 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext

link to Alz & dementia journal pub showing study report. Testing done w/AD patients while they are early in diagnosis for AD. I can see how it would be possible for AVXL to use such a tool and obviate the time period lost by conventional trials.

My own comment is that all of this is about time. People lose time from their lives when they have AD. Little girls lose time and their parents wait. All CNS diseases steal time and function. Time is money.

It is looking more and more like AVXL will link with Cognision-Nuronetrix and together they will present a service for diagnosis and treatment of various CNS diseases, starting with AD. Massive. More to follow. BTW, this is all IMO.

[Lima4918]

Nidan and Investor,

This extract from the patent answers the question of who this "on and off again" Anavex treatment method was performed on. It was performed on 12 of the remaining Alz patients from the original Aussie trial. Small group but this answers the question as to the company's tinkering with the protocol. I mean, it never was a slam dunk as to what dosage amount was optimal, how often, etc. This patent may provide some insight on how Anavex may want to treat the patients in the trials?


Could this be a reason for the holdup of registration?


Company stated it was dosing as "planned" and I believe them, but their probably dosing in this "on and off" fashion?